Recent news on Biopharma Sentiment Index (BPSI)
Biopharma Sentiment Index; BPSI; Endpoints News; biopharma sentiment survey; drug development sentiment; biotech investing sentiment; pharma industry outlook
Recent news on ACIP’s hepatitis B birth‑dose recommendation
ACIP; hepatitis B; birth dose; infant vaccination; shared clinical decision-making; CDC immunization schedule; pregnancy screening; hepatitis B policy change
Rapport Therapeutics Reports Updated Phase 2a Data for Seizure Drug RAP-219
Rapport Therapeutics; RAP-219; Phase 2a trial; seizure drug; epilepsy; focal onset seizures; clinical seizure reduction; FDA meeting; Phase 3 trials
Building the Next Generation of Biologics: Inside the Future of Protein Engineering
next-generation biologics; protein engineering; bispecific antibodies; antibody-drug conjugates (ADCs); protein degraders; PROTACs; molecular glues; mini-proteins; AI in protein design; manufacturability; structural biology; cryo-EM; high-throughput protein production; generative biology
UniQure restates FDA’s negative feedback on Huntington’s trial; Neurimmune expands AstraZeneca alliance
UniQure; AMT-130; FDA feedback; external control group; gene therapy; Neurimmune; AstraZeneca; neurodegeneration; antibody collaboration; licensing deal; biopharmaceutical partnerships
Crescent Biopharma and Kelun-Biotech Announce Reciprocal Licensing Pact for PD-1xVEGF and ADC Cancer Therapies
Crescent Biopharma; Kelun-Biotech; PD-1xVEGF; CR-001; SKB105; reciprocal licensing; oncology partnership; China; ADC; bispecific antibody
FDA names Tracy Beth Heg as acting CDER chief
Tracy Beth Heg; acting CDER chief; FDA leadership; Center for Drug Evaluation and Research; COVID-19 vaccine safety; drug regulation; U.S. Food and Drug Administration
Former FDA Chiefs Criticize Proposed Vaccine Policy Changes at ACIP Meeting
former FDA commissioners; CDC; ACIP meeting; vaccine policy changes; COVID-19 vaccines; Vinay Prasad; Center for Biologics Evaluation and Research; vaccine safety regulation; Senator Bill Cassidy; New England Journal of Medicine commentary
Bristol Myers Squibb Delays Cobenfy Alzheimer’s Psychosis Trial Readout Due to Site Irregularities
Bristol Myers Squibb; Cobenfy; Alzheimer’s psychosis; ADEPT-2 trial; trial site irregularities; Phase III study; delay; 2026
Jesper Høiland Joins Alva Therapeutics’ Board of Directors
Alva Therapeutics; Board of Directors; Novo Nordisk; Type 2 diabetes; obesity; oral incretin secretagogue; clinical development; pharmaceutical commercialization